News

PipelineReview.com14h

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 ...
PipelineReview.com13h

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

(Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and ...
PipelineReview.com14h

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other ...
PipelineReview.com14h

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, Iceland and LONDON, UK I August 21, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of ...
PipelineReview.com14h

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...
PipelineReview.com1d

NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment

An imaging-based analysis of animals treated with ExoPTEN after a spinal cord injury showed more organized spinal cord tissue ...
PipelineReview.com1d

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

CRANBURY, NJ, USA I, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a ...
PipelineReview.com2d

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

CONSHOHOCKEN, PA, USA I August 19, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...
PipelineReview.com2d

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Company’s second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - ...
PipelineReview.com2d

Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma

inMMyCAR is a multi-center Phase 1, open-label, dose-escalation clinical trial designed to assess the safety and preliminary efficacy of a single dose of KLN-1010. The first patient was dosed at Royal ...
PipelineReview.com2d

Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA

SHANGHAI, China I August 19, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed ...
PipelineReview.com2d

VASTHERA Receives U.S. FDA Clearance to initiate Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

SEOUL, South Korea I August 19, 2025 I On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the ...